In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates

Mycoses ◽  
2021 ◽  
Author(s):  
Jiacheng Dong ◽  
Guanzhao Liang ◽  
Hailin Zheng ◽  
Siyue Kan ◽  
Nana Song ◽  
...  
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Auris

scholarly journals In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae

2019 ◽  
Vol 74 (12) ◽  
pp. 3505-3510 ◽  
Author(s):  
Zoltán Tóth ◽  
Lajos Forgács ◽  
Jeffrey B Locke ◽  
Gábor Kardos ◽  
Fruzsina Nagy ◽  
...  
Keyword(s):  
Saccharomyces Cerevisiae ◽  
Amphotericin B ◽  
Candida Species ◽  
Sensu Stricto ◽  
Candida Guilliermondii ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Auris ◽  
In Vitro Susceptibility

Abstract Background Rezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species. Methods We determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as Saccharomyces cerevisiae. The activity of rezafungin was compared with that of anidulafungin, caspofungin, micafungin, amphotericin B and fluconazole, using CLSI broth microdilution methodology (Fourth Edition: M27). Results Rezafungin MIC90 values were 0.06 mg/L for Candida albicans (n=125), Candida tropicalis (n=51), Candida dubliniensis (n=22), Candida inconspicua (n=41), Candida sojae (n=10), Candida lipolytica (n=10) and Candida pulcherrima (n=10), 0.12 mg/L for Candida glabrata (n=81), Candida krusei (n=53), Candida kefyr (n=52) and Candida fabianii (n=15), 0.25 mg/L for Candida lusitaniae (n=46) and Candida auris (n=19), 0.5 mg/L for Candida metapsilosis (n=15) and S. cerevisiae (n=21), 1 mg/L for Candida orthopsilosis (n=15) and Candida guilliermondii (n=27) and 2 mg/L for Candida parapsilosis sensu stricto (n=59). Caspofungin MIC90 values were 0.25–2 mg/L for all species, while micafungin and anidulafungin MIC90 values were similar to those of rezafungin. Fluconazole resistance was found in C. albicans (5.6%) and C. glabrata (4.9%); rezafungin was effective against these isolates as well. Amphotericin B MIC values did not exceed 2 mg/L. Conclusions Rezafungin showed excellent in vitro activity against both WT and azole-resistant Candida species, as well as against S. cerevisiae. Rezafungin had similar activity to other echinocandins (excluding caspofungin) against common Candida species and, notably, against clinically relevant uncommon Candida species.

Antifungal activity of nikkomycin Z against Candida auris

2021 ◽  
Author(s):  
Meghan L Bentz ◽  
Natalie Nunnally ◽  
Shawn R Lockhart ◽  
D Joseph Sexton ◽  
Elizabeth L Berkow
Keyword(s):  
Fungal Pathogen ◽  
Competitive Inhibitor ◽  
Chitin Synthase ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Auris ◽  
Fungal Cell ◽  
The World ◽  
Nikkomycin Z

Abstract Background Nikkomycin Z is a competitive inhibitor of chitin synthase—an enzyme needed for synthesis of the fungal cell wall. Nikkomycin Z shows promise as a treatment for coccidioidomycoses and mixed activity has been described against other fungi and yeast. To our knowledge, it has not previously been tested against the emerging fungal pathogen Candida auris. Objectives To determine the in vitro activity of nikkomycin Z against C. auris. Methods Nikkomycin Z was tested by broth microdilution against a panel of 100 isolates of genetically diverse C. auris from around the world. Results Nikkomycin Z showed mixed activity against the tested isolates, with an MIC range of 0.125 to >64 mg/L. The MIC50 and MIC90 were 2 and 32 mg/L, respectively. Conclusions These findings suggest nikkomycin Z has in vitro activity against some, but not all isolates of C. auris.

scholarly journals 733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S417-S417
Author(s):  
Katyna Borroto-Esoda ◽  
David A Angulo ◽  
Nkechi Azie
Keyword(s):  
Vitro Activity ◽  
Multi Drug Resistance ◽  
In Vitro Activity ◽  
Candida Auris ◽  
In Vitro Susceptibility ◽  
Healthcare Facilities ◽  
Highly Active ◽  
Synthase Inhibitor ◽  
Global Threat

Abstract Background Candida auris is an urgent global threat; a pathogen associated with high mortality (up to 60%), multi-drug resistance, the ability to spread from person-to-person and surface-to-person, presenting high risk for outbreaks in healthcare facilities. Echinocandins are the first-line treatment for patients with Candida auris infections given the high degree of resistance to azoles and polyenes. Ibrexafungerp is a novel IV/oral glucan synthase inhibitor (triterpenoid) antifungal with activity against Candida, Aspergillus and Pneumocystis spp, in Phase 3 development. We will present a compilation of >400 Candida auris isolates from four studies, including 32 Candida auris isolates with elevated MIC’s to the echinocandins. Methods In vitro MIC data for ibrexafungerp against Candida auris isolates were compiled from across 4 independent studies with the majority of isolates originating in the US and India. In vitro susceptibility was determined by broth micro-dilution using CLSI (M27-S3) and/or EUCAST methods. Overall, 445 isolates were evaluated including 32 isolates with elevated MIC values to one or more echinocandins. Results The ibrexafungerp MIC90 value against the 445 clinical isolates was 1 μg/mL; the modal and MIC50 values were 0.5 μg/mL each. These results were consistent across the four studies and no differences were observed between MIC results generated using CLSI or EUCAST methods. Similar results were obtained for the 32 isolates with elevated MIC values to one or more of the echinocandins. Among this population, the mode, MIC50 and MIC90 were 0.5, 0.5, and 1 μg/mL, respectively. Only 1/32 of the echinocandin-resistant isolates had reduced sensitivity to ibrexafungerp (defined as > 2-dilutions vs the mode). This isolate was pan-resistant with elevated MICs to all three echinocandins (MICs = 4 μg/mL) as well as fluconazole (MIC >256 μg/mL) and amphotericin B (MIC = 1 μg/mL). Conclusion This data demonstrates that ibrexafungerp possesses potent and consistent in vitro activity against Candida auris and remains highly active against C. auris isolates with high MIC’s to the echinocandins. Disclosures Katyna Borroto-Esoda, PhD, SCYNEXIS, Inc. (Employee, Shareholder) David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder) Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder)

In Vitro Activity of Phytocannabinoids from High Potency Cannabis sativa

Planta Medica ◽  
2012 ◽  
Vol 78 (05) ◽  
Author(s):  
A Husni ◽  
S Ross ◽  
O Dale ◽  
C Gemelli ◽  
G Ma ◽  
...  
Keyword(s):  
Cannabis Sativa ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
High Potency
Sign in / Sign up

Export Citation Format

Share Document